SELLAS Life Sciences Group, Inc. hosted a virtual panel discussion on the treatment landscape for acute myeloid leukemia (AML) and the potential for GFH009 to address unmet medical needs for patients with relapsed and/or refractory AML.
AI Assistant
SELLAS LIFE SCIENCES GROUP INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.